Triple data take Nuvalent's market cap above $3bn
After touting NVL-655 as being active in patients resistant to a third-generation ALK inhibitor, Nuvalent now has clinical data to back this up.
Triple meeting 2023 preview – firsts for Amgen and Novartis
But Repare and Black Diamond still have rebuilding to do.
Lumakras is the next test of FDA’s hardening stance
After Exkivity signals another accelerated approval slowdown the Amgen drug tomorrow faces an adcom over its own conditional approval.
What’s that, a win for CD47?
ALX Oncology claims the first ever success for a CD47 inhibitor in a global randomised solid tumour study.
Another twist in Cardiff’s onvansertib plan
Front-line phase 3 plans take shape, as the company claims a new success, this time in pancreatic cancer.
Bristol seeks novelty in TIGIT
Disclosure of BMS-986442’s second target antigen endorses Agenus, and is highly relevant for GSK and Compugen too.
